Glucocorticoid remediable aldosteronism (GRA) is an autosomal dominant cause of primary aldosteronism and high blood pressure resulting from a chimeric 11␤-hydroxylase/aldosterone synthase gene. Abnormal expression of aldosterone synthase causes primary aldosteronism, which can be inhibited by glucocorticoids. Diagnosis of GRA has depended on the identification of a restriction enzyme product in genomic DNA of affected individuals. Recently, a two-tube long PCR method was described that allowed diagnosis of GRA in a kindred in Australia. A similar long PCR method confirmed the diagnosis of GRA in members of five northeastern Scotland families previously identified by Southern blotting and detected affected members of five GRA families previously identified in Glasgow. A multiplex PCR protocol is described here that allows the control aldosterone synthase amplification and chimeric gene amplification to be carried out in the same tube. We describe the regions of cross-over in each of 10 kindreds identified in Scotland. To identify cross-over regions in each of the kindreds, the chimeric long PCR product was cloned and sequenced. Five cross-over sites were identified ranging from intron 2 to exon 4, indicating the reliability of the method in identifying chimeric genes resulting from different sites of cross-over. (J Clin Endocrinol Metab 83: 4328 -4331, 1998) G LUCOCORTICOID remediable aldosteronism (GRA) is an autosomal dominant cause of primary aldosteronism and high blood pressure reversed by the administration of dexamethasone. GRA was originally reported in 1966 by Sutherland and co-workers (1) who described hypertension, hypokalemia, aldosteronism, and suppressed renin activity in a father and his son.
G LUCOCORTICOID remediable aldosteronism (GRA) is
an autosomal dominant cause of primary aldosteronism and high blood pressure reversed by the administration of dexamethasone. GRA was originally reported in 1966 by Sutherland and co-workers (1) who described hypertension, hypokalemia, aldosteronism, and suppressed renin activity in a father and his son.
The late stages of aldosterone synthesis are catalyzed by the P450 enzyme aldosterone synthase, which is capable of the 11-and 18-hydroxylation reactions necessary in the synthesis of the steroid. The enzyme is encoded by the gene CYP11B2, whose expression is limited to the zona glomerulosa of the adrenal cortex and is regulated by angiotensin II and K ϩ . In contrast, the final 11␤ hydroxylation in the synthesis of cortisol in the zona fasciculata is regulated by 11␤-hydroxylase, which is encoded by the gene CYP11B1. The expression of this gene is principally regulated by ACTH. CYP11B1 and CYP11B2 share a high degree of nucleotide homology (Ͼ93% for exons), and this results in the synthesis of proteins with great similarity at the amino acid sequence level. In GRA, the clinical and biochemical abnormalities reflect the regulation of aldosterone synthase activity by ACTH rather than angiotensin II.
In 1992 Lifton et al. (2, 3) described the presence of a chimeric CYP11B1/CYP11B2 gene in patients with GRA. The chimeric gene contains the 5Ј regulatory sequence of CYP11B1 fused to the 3Ј structural sequence of CYP11B2, so that the chimeric gene produces a protein with aldosterone synthase activity in response to ACTH. The consequent abnormal expression of aldosterone synthase results in primary aldosteronism, which can be inhibited by glucocorticoids.
In GRA the cross-over region between the CYP11B1 and CYP11B2 genes can occur anywhere from the start of intron 2 to the end of exon 4 of the corresponding genes. Studies with complementary DNA constructs of CYP11B2 show that sequences encoded by exons 3Ј of exon 5 are necessary for the preservation of aldosterone synthase activity (4, 5) . The diagnosis of GRA has depended on identification by Southern blotting of an abnormal fragment in genomic DNA from affected individuals (2) . However, this is a time-consuming method that is unsuitable for rapid screening of large numbers of samples.
Recently, a two-tube (externally controlled) long PCR method was described that allowed the diagnosis of GRA in the members of one GRA kindred in Australia (6) . We used a similar method to confirm the diagnosis of GRA in the members of five families from northeast Scotland previously identified by Southern blotting. This method was also used to positively identify affected members of five additional GRA families previously described in Glasgow (7) .
We also describe here a multiplex PCR protocol that allows the control aldosterone synthase amplification to be carried out in the same tube as the test chimeric gene amplification. This test has proven as reliable as the original two-tube long PCR protocol but has the advantage of using an internal control.
To identify the region of cross-over in each of the 10 kindreds, the chimeric long PCR product was cloned and sequenced. Five cross-over sites were identified ranging from intron 2 to exon 4, indicating the reliability of the method in identifying chimeric genes resulting from different sites of cross-over.
Materials and Methods

Two-tube PCR amplification of chimeric gene sequence
Genomic DNA was extracted from peripheral blood leukocytes using a commercial kit following the protocol of Jonsson et al. (6) (Genomix, Hoefer U.K., Newcastle-Under-Lyme, U.K.). Genomic DNA from family members previously diagnosed by Southern blotting as having or not having GRA was subjected to amplification. Primers (Table 1) for the 5Ј untranslated region of CYP11B1 (XL-1a) and a reverse primer hybridizing to exon 5 of CYP11B2 (XL-2a) were used to amplify the chimeric gene. A third primer (XL-3) was used in a separate reaction with primer XL-2a to amplify CYP11B2 and act as a control for the integrity of the long PCR. For PCR, the Expand High Fidelity DNA polymerase kit (Boehringer Mannheim, Mannheim, Germany) and 2.6 U of Expand High Fidelity PCR system enzyme mix was used. Reactions included a hot start at 95 C for 1 min, continued with 12 cycles of 95 C for 1 min and 68 C for 5 min, followed by 18 cycles of 95 C for 1 min and 68 C for 5 mins with a 30-sec extension per cycle.
Multiplex long PCR
To avoid using a separate tube containing a control reaction, we designed a further 5Ј forward primer (XL-4 Table 1 ), which was incorporated into a multiplex primer set including XL-1b and 2b. In our multiplex long PCR one set of primers (XL-4 and XL-2b) yields a 4.0-kilobase (kb) fragment from the normal CYP11B2 gene, whereas the other set (XL-1b and XL-2b) yields a 3.9-kb fragment from the chimeric gene. A single (4.0 kb) product indicates the presence of a normal aldosterone synthase gene, and the presence of an additional band at 3.9 kb indicates the presence of a chimeric crossover product (Fig. 1) . The PCR conditions were identical to the two-tube assay described above.
Cloning of chimeric gene amplification product
DNA from a GRA-positive representative from each family was subjected to PCR amplification as described above. The 3.9-kb chimeric PCR product was separated by excision of the DNA-containing band from ethidium bromide-stained agarose gel. The isolated DNA was restricted with 10 U EcoRI (Promega Corp., Madison, WI) at 37 C for 1 h. Restricted DNA was removed from the reaction using the Qiaex II extraction matrix (Qiagen, Chatsworth, CA) and cloned into EcoRI linearized pGEM-3Z plasmid. Ligation was carried out at 4 C for 16 h and half of the ligation reaction used to transform competent DH5-␣ cells (Life Technologies, Gaithersburg, MD). Recombinant colonies were identified using blue/ white screening and plasmid extracted using the Qiagen Plasmid Extraction Kit (Qiagen) following the manufacturer's protocols.
Sequence analysis of cloned chimeric PCR product
Sequence analysis was performed using the dideoxy chain termination method (8) and an ABI automated sequencer (ABI 377, Applied Biosystems Inc., Perkin-Elmer, Norwalk, CT). Primers for the chimeric gene in forward and reverse orientations, as well as universal and reverse for the pGEM-3Z vector were used. Cross-over regions were determined by comparison of sequence obtained with the CYP11B1 and CYP11B2 sequences (9) .
Results
Rapid diagnosis of GRA using long PCR
Two-tube long PCR. DNA from members of all five kindreds in northeast Scotland as well as DNA from members of the Primers XL-1a and XL-2a have EcoR1 restriction endonuclease sites (indicated) at 5Ј end to allow ligation into EcoR1 linearized pGEM-3Z vector. These primers were used in original two-tube assay. Primers 1b and 2b are essentially same as 1a and 2a but do not contain EcoR1 sites at their 5Ј end. These primers were used in single-tube assay.
FIG. 1.
A, Diagrammatic representation of normal associations of genes CYP11B1 and CYP11B2. All individuals will produce a PCR product when primers XL-3 and XL-2a are used to amplify CYP11B2. No product will be generated using a primer pair specific for chimeric gene (XL-1a and XL-2a). B, Diagrammatic representation of associations of CYP11B1 and CYP11B2 with chimeric gene in GRA. Again, product is obtained from use of primers XL-3 and XL-2a. Presence of chimeric gene allows PCR product to be generated using primers XL-1a and XL-2a. C and D, Diagrammatic representation of relative positions of primers used in multiplex PCR. In multiplex PCR a primer mix consisting of primers XL-1b, XL-2b, and XL-4 was used in all reactions. In hybridization of both control CYP11B2 and chimeric gene, primer XL-2b is reverse primer. Primer XL-4 (forward primer in CYP11B2 amplification) is 160 bp upstream of primer XL-1b (forward primer in chimeric gene amplification). This gives rise to a control (CYP11B2) fragment of 4.0 kb compared with a chimeric gene amplification product of 3.9 kb. Difference in size of two products allows reaction to be carried out in one tube and different-sized products to be separated using agarose gel electrophoresis. NB. Primers XL1a and XL1b differ only in that XL1a incorporates an EcoRI site at 5Ј end. Primers XL2a and XL-2b differ in same way.
five kindreds previously described in Glasgow were amplified using the two-tube long PCR protocol. In total, 33 individuals with GRA were found to exhibit a band at 3.9 kb on amplification using the primers specific for the chimeric gene. Twenty members of our five kindreds known not to have GRA (as determined by Southern blotting) did not produce a band when their DNA was amplified with the chimeric gene primers. No false positives were found. Furthermore, all GRA-negative patients produced a normal product from the aldosterone synthase (control) primers, indicating that the negative results were because of the absence of a chimeric gene and not PCR failure.
Multiplex long PCR.
We also tested the same positive and negative family members as above using the multiplex, single-tube long PCR method. This method produced a 4.0-kb control CYP11B2 product in the same reaction as the 3.9-kb chimeric band in all known GRA-positive individuals. All confirmed GRA-negative samples produced only the 4.0-kb control product.
Identification of cross-over points in GRA kindreds
Sequencing of cloned chimeric gene amplification product from the 10 available kindreds identified five different areas of cross-over (Fig. 2) . It is impossible to describe the exact point of cross-over in each case because of the high level of homology between the CYP11B1 and CYP11B2 genes, so cross-over sites are allocated to regions of each gene. Kindreds 1, 4, and 5 all have indistinguishable cross-over re- gions. These kindreds have a chimeric gene containing CYP11B1 sequence as far as the end of intron 3 and CYP11B2 sequence from then onwards. Similarly, kindreds 3, 6, 7, and 8 possess indistinguishable chimeric genes comprising exons 1-3 of CYP11B1 and exons 4 -9 of CYP11B2. Kindred 2 possesses a chimeric gene with a cross-over in intron 2. Kindreds 9 and 10 possess mutant genes in which the cross-over occurs in the middle and end of exon 4, respectively. [Kindreds 6 -10 cross-over data was originally published by Jamieson et al. (7)].
Discussion
The original description of the two-tube long PCR method to diagnose GRA was limited to one kindred who all share the same chromosomal gene structure. We have now extended this method to a large number of the family members from 10 GRA kindreds previously identified by a Southern blot technique. All individuals found to have GRA by Southern blotting were also found to be GRA-positive using this method. GRA-negative patients were also correctly identified. The fact that the individuals tested had a range of cross-over sites extending from intron 2 to the end of intron 4 suggests that this technique should identify the chimeric gene in all kindreds published to date. It is therefore reasonable to suggest that the long PCR technique can be used reliably as a rapid technique for diagnosing GRA.
The novel multiplex adaptation was tested in the same way to ensure its reliability. The same known GRA-positive and -negative individuals were tested, and in each case the technique proved both specific and sensitive. This technique has the advantage over the two-tube assay in that the control reaction is incorporated into the same tube as the amplification of the chimeric gene and is a more valid measure of reaction integrity. This assay has proved reliable and is now our method of choice for routine diagnosis of GRA.
Of the five GRA-positive families identified in the northeast of Scotland, three have completely indistinguishable cross-over regions. This suggests that the families share a common ancestor. However a more detailed haplotype analysis would be required to prove this conclusively. The crossover region identified in kindred 3 is the same as that previously described in three of the GRA families in Glasgow (7) . A large proportion of the GRA families in Lifton et al.'s (2, 3) report in the United States were of Irish ancestry; the Irish and Scots have common ancestors in the Celtic races of the 6th century, and it is possible that because of this the chimeric gene linked to GRA occurs from a series of ancient mutations that have a higher incidence in people of Celtic ancestry. The fact that we identified similar cross-over regions in our families would seem to support this theory. It is of interest that kindred 2 had a cross-over region upstream of any previously described in any Scottish family; kindred 2 originated in the Shetland Isles and may be of Nordic rather than Celtic descent. This would again support the theory of a series of founder effects for GRA, because people inheriting the chimeric gene from different populations would have different sites of cross-over.
